Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

One way to cope with cuts in HIV prevention funding is to continue to push to increase the number of people who self-test for HIV instead of getting tested at a clinic or hospital, experts at a series ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

Experts are celebrating a breakthrough in HIV prevention. Doctors say it could mean we're one step closer to eradicating the ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The WHO issued a global recommendation for lenacapavir, a highly effective, twice-yearly injection to prevent HIV infection. The recommendation follows a recent FDA approval for the drug, which ...

Twice-yearly shot could improve PrEP adherence rates Despite advancements in HIV treatment and prevention, in 2023, more than 100 people were diagnosed with HIV every day in the United States.

In his rescissions request to Congress last month, President Donald Trump asked that the hundreds of millions dollars budgeted for the President's Emergency Plans for AIDS Relief, or PEPFAR, be ...